{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:20:16Z","timestamp":1788261616098,"version":"build-2803163510"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014269","name":"Uniwersytet Medyczny w Bia\u0142ymstoku","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005297","name":"Medical University of Bialystok","doi-asserted-by":"publisher","award":["N\/ST\/ZB\/16\/001\/3309"],"award-info":[{"award-number":["N\/ST\/ZB\/16\/001\/3309"]}],"id":[{"id":"10.13039\/501100005297","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ejim.2026.106893","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T11:38:42Z","timestamp":1776857922000},"page":"106893","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Fatty acid binding protein 4, resistin, diastolic dysfunction, and cardiovascular risk in patients with rheumatoid arthritis"],"prefix":"10.1016","volume":"151","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1609-3793","authenticated-orcid":false,"given":"Mariusz","family":"Cio\u0142kiewicz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kuryliszyn-Moskal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Jab\u0142o\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wioletta","family":"Ratajczak-Wrona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Dakowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr A.","family":"Klimiuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejim.2026.106893_bib0001","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1016\/S2665-9913(20)30221-6","article-title":"Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout","volume":"3","author":"Hansildaar","year":"2021","journal-title":"Lancet Rheumatol"},{"issue":"34","key":"10.1016\/j.ejim.2026.106893_bib0002","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"ESC National Cardiac Societies; ESC Scientific Document Group. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J."},{"key":"10.1016\/j.ejim.2026.106893_bib0003","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.berh.2016.10.006","article-title":"Cardiovascular disease in inflammatory rheumatic diseases","volume":"30","author":"Casta\u00f1eda","year":"2016","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.ejim.2026.106893_bib0004","doi-asserted-by":"crossref","first-page":"262","DOI":"10.2174\/1381612824666180123102632","article-title":"Inflammatory arthritis and heart disease","volume":"24","author":"Castaneda","year":"2018","journal-title":"Curr Pharm Des"},{"issue":"1","key":"10.1016\/j.ejim.2026.106893_bib0005","first-page":"135","article-title":"The association between rheumatoid arthritis and left ventricular diastolic dysfunction: pathogenesis, predictors and managements","volume":"43","author":"Qian","year":"2025","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"10.1016\/j.ejim.2026.106893_bib0006","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s10554-020-02057-3","article-title":"Subclinical ventricular dysfunction in rheumatoid arthritis","volume":"37","author":"Rodrigues","year":"2021","journal-title":"Int J Cardiovasc Imaging"},{"issue":"4","key":"10.1016\/j.ejim.2026.106893_bib0007","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s10067-018-4369-7","article-title":"Diastolic dysfunction in rheumatoid arthritis patients with low disease activity","volume":"38","author":"Targo\u0144ska-St\u0119pniak","year":"2019","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.ejim.2026.106893_bib0008","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1186\/s13075-021-02629-1","article-title":"Accelerated diastolic dysfunction in premenopausal women with rheumatoid arthritis","volume":"23","author":"Kim","year":"2021","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.ejim.2026.106893_bib0009","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1756-185X.2010.01593.x","article-title":"A cross-sectional study of diastolic dysfunction in rheumatoid arthritis and its association with disease activity","volume":"14","author":"Abdul Muizz","year":"2011","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.ejim.2026.106893_bib0010","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/s12016-017-8635-2","article-title":"Sex and cardiovascular involvement in inflammatory joint diseases","volume":"56","author":"Casta\u00f1eda","year":"2019","journal-title":"Clin Rev Allergy Immunol"},{"issue":"4","key":"10.1016\/j.ejim.2026.106893_bib0011","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1194\/jlr.S091793","article-title":"Adipokine FABP4 integrates energy stores and counterregulatory metabolic responses","volume":"60","author":"Prentice","year":"2019","journal-title":"J Lipid Res"},{"issue":"1","key":"10.1016\/j.ejim.2026.106893_bib0012","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41413-022-00211-2","article-title":"FABP4 secreted by M1-polarized macrophages promotes synovitis and angiogenesis to exacerbate rheumatoid arthritis","volume":"10","author":"Guo","year":"2022","journal-title":"Bone Res"},{"issue":"2","key":"10.1016\/j.ejim.2026.106893_bib0013","doi-asserted-by":"crossref","DOI":"10.1038\/nutd.2014.3","article-title":"Adipocyte fatty acid-binding protein levels are associated with left ventricular diastolic dysfunction in morbidly obese subjects","volume":"4","author":"Baessler","year":"2014","journal-title":"Nutr Diabetes"},{"issue":"1","key":"10.1016\/j.ejim.2026.106893_bib0014","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s12933-020-01167-5","article-title":"Association between adipocyte fatty acid-binding protein with left ventricular remodelling and diastolic function in type 2 diabetes: a prospective echocardiography study","volume":"19","author":"Wu","year":"2020","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"10.1016\/j.ejim.2026.106893_bib0015","doi-asserted-by":"crossref","first-page":"645","DOI":"10.3390\/antiox12030645","article-title":"Fatty acid binding proteins 3 and 4 predict both all-cause and cardiovascular mortality in subjects with chronic heart failure and type 2 diabetes mellitus","volume":"12","author":"Rodr\u00edguez-Calvo","year":"2023","journal-title":"Antioxidants (Basel)"},{"issue":"15","key":"10.1016\/j.ejim.2026.106893_bib0016","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.2217\/bmm-2020-0284","article-title":"Elevated expression of FABP4 is associated with disease activity in rheumatoid arthritis patients","volume":"14","author":"Chen","year":"2020","journal-title":"Biomark Med"},{"issue":"1","key":"10.1016\/j.ejim.2026.106893_bib0017","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.cyto.2013.05.001","article-title":"The level of fatty acid-binding protein 4, a novel adipokine, is increased in rheumatoid arthritis and correlates with serum cholesterol levels","volume":"64","author":"Andr\u00e9s Cerezo","year":"2013","journal-title":"Cytokine"},{"issue":"1","key":"10.1016\/j.ejim.2026.106893_bib0018","doi-asserted-by":"crossref","DOI":"10.2174\/1573403X17666210729101120","article-title":"Resistin and Cardiovascular disease: A review of the current literature regarding clinical and pathological relationships","volume":"18","author":"Askin","year":"2022","journal-title":"Curr Cardiol Rev"},{"key":"10.1016\/j.ejim.2026.106893_bib0019","doi-asserted-by":"crossref","first-page":"S134","DOI":"10.1016\/j.acvd.2023.10.292","article-title":"The role of resistin in the formation of dyastolic dysfunction in patients with type 2 diabetes mellitus and overweight","volume":"117","author":"Zhuravlyova","year":"2024","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.ejim.2026.106893_bib0020","first-page":"4","article-title":"Resistin is a novel biomarker for a risk of heart failure","volume":"1","author":"Takeishi","year":"2013","journal-title":"J Cardiovasc Dis Diagn"},{"issue":"5","key":"10.1016\/j.ejim.2026.106893_bib0021","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1002\/ehf2.14064","article-title":"Resistin and risks of incident heart failure subtypes and cardiac fibrosis: the Multi-Ethnic Study of Atherosclerosis","volume":"9","author":"Cai","year":"2022","journal-title":"ESC Heart Fail"},{"issue":"Supplement_1","key":"10.1016\/j.ejim.2026.106893_bib0022","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehab724.1105","article-title":"Differential prognostic value of resistin for cardiovascular death in patients with stable coronary artery disease according to the presence of metabolic syndrome","volume":"42","author":"Kosmas","year":"2021","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.ejim.2026.106893_bib0023","doi-asserted-by":"crossref","first-page":"192","DOI":"10.5114\/reum.2022.117839","article-title":"Evaluation of the adipokine profile (adiponectin, resistin, adipsin, vaspin, and leptin) in patients with early rheumatoid arthritis and its correlation with disease activity","volume":"60","author":"Magali Chamorro-Melo","year":"2022","journal-title":"Reumatologia"},{"issue":"2","key":"10.1016\/j.ejim.2026.106893_bib0024","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3390\/biom11020325","article-title":"Adipocytokines in untreated newly diagnosed rheumatoid arthritis: association with circulating chemokines and markers of inflammation","volume":"11","author":"Vasileiadis","year":"2021","journal-title":"Biomolecules"},{"issue":"6","key":"10.1016\/j.ejim.2026.106893_bib0025","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.bj.2019.01.007","article-title":"Incidence and effect of insulin resistance on progression of atherosclerosis in rheumatoid arthritis patients of long disease duration","volume":"42","author":"Guin","year":"2019","journal-title":"Biomed J"},{"issue":"12","key":"10.1016\/j.ejim.2026.106893_bib0026","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1080\/03007995.2019.1654988","article-title":"Changes in serum adipokines profile and insulin resistance in patients with rheumatoid arthritis treated with anti-TNF-\u03b1","volume":"35","author":"Corrado","year":"2019","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"10.1016\/j.ejim.2026.106893_bib0027","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1080\/03009742.2021.1929456","article-title":"Pretreatment resistin levels are associated with erosive disease in early rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs and infliximab","volume":"51","author":"Vuolteenaho","year":"2022","journal-title":"Scand J Rheumatol"},{"issue":"9","key":"10.1016\/j.ejim.2026.106893_bib0028","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.ejim.2026.106893_bib0029","doi-asserted-by":"crossref","first-page":"R796","DOI":"10.1186\/ar1740","article-title":"Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score","volume":"7","author":"Aletaha","year":"2005","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"10.1016\/j.ejim.2026.106893_bib0030","first-page":"982","article-title":"Which HAQ is best? A comparison of the HAQ, MHAQ and RA-HAQ, a difficult 8 item HAQ (DHAQ), and a rescored 20 item HAQ (HAQ20): analyses in 2491 rheumatoid arthritis patients following leflunomide initiation","volume":"28","author":"Wolfe","year":"2001","journal-title":"J Rheumatol"},{"issue":"8","key":"10.1016\/j.ejim.2026.106893_bib0031","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1002\/art.39195","article-title":"Derivation and internal validation of an expanded cardiovascular risk prediction score for rheumatoid arthritis: a Consortium of Rheumatology Researchers of North America Registry Study","volume":"67","author":"Solomon","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ejim.2026.106893_bib0032","unstructured":"https:\/\/www.verityresearch.org\/cvd-risk-calculator\/(accessed on 24 March 2025)."},{"key":"10.1016\/j.ejim.2026.106893_bib0033","article-title":"Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study","volume":"357","author":"Hippisley-Cox","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.ejim.2026.106893_bib0034","doi-asserted-by":"crossref","unstructured":"https:\/\/qrisk.org\/(accessed on 24 March 2025).","DOI":"10.32964\/TJ24.3"},{"key":"10.1016\/j.ejim.2026.106893_bib0035","unstructured":"https:\/\/heartscore.escardio.org\/Calculate\/quickcalculator.aspx?model=high (accessed on 24 March 2025)."},{"key":"10.1016\/j.ejim.2026.106893_bib0036","unstructured":"https:\/\/u-prevent.com\/calculators\/score2Diabetes (accessed on 24 March 2025)."},{"issue":"14","key":"10.1016\/j.ejim.2026.106893_bib0037","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1093\/eurjpc\/zwae174","article-title":"Prediction of individual lifetime cardiovascular risk and potential treatment benefit: development and recalibration of the LIFE-CVD2 model to four European risk regions","volume":"31","author":"Hageman","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.ejim.2026.106893_bib0038","unstructured":"https:\/\/u-prevent.com\/calculators\/lifeCvd2 (accessed on 24 March 2025)."},{"key":"10.1016\/j.ejim.2026.106893_bib0039","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","article-title":"Recommendations for cardiac chamber quantification by Echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"28","author":"Lang","year":"2015","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.ejim.2026.106893_bib0040","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.echo.2016.01.011","article-title":"Recommendations for the evaluation of left ventricular diastolic function by Echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"29","author":"Nagueh","year":"2016","journal-title":"J AmSoc Echocardiogr"},{"issue":"12","key":"10.1016\/j.ejim.2026.106893_bib0041","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.7150\/ijms.25588","article-title":"High levels of serum adipocyte fatty acid-binding protein predict cardiovascular events in coronary artery disease patients","volume":"15","author":"Huang","year":"2018","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.ejim.2026.106893_bib0042","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12933-014-0126-7","article-title":"Elevation of circulating fatty acid-binding protein 4 is independently associated with left ventricular diastolic dysfunction in a general population","volume":"13","author":"Fuseya","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.ejim.2026.106893_bib0043","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ijcard.2019.04.031","article-title":"Plasma FABP4 levels are associated with left atrial fat volume in persistent atrial fibrillation and predict recurrence after catheter ablation","volume":"292","author":"Lopez-Canoa","year":"2019","journal-title":"Int J Cardiol"},{"issue":"19","key":"10.1016\/j.ejim.2026.106893_bib0044","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231911107","article-title":"The role of fatty acid-binding protein 4 in the characterization of atrial fibrillation and the prediction of outcomes after catheter ablation","volume":"23","author":"L\u00f3pez-Canoa","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"Supplement_2","key":"10.1016\/j.ejim.2026.106893_bib0045","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehad655.3218","article-title":"High FABP4, associated with low-voltage areas, increases the epicardial fibrosis and its glucose metabolism","volume":"44","author":"Vazquez-Abuin","year":"2023","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.ejim.2026.106893_bib0046","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.yjmcc.2007.08.009","article-title":"Resistin, an adipocytokine, offers protection against acute myocardial infarction","volume":"43","author":"Gao","year":"2007","journal-title":"J Mol Cell Cardiol"},{"issue":"1","key":"10.1016\/j.ejim.2026.106893_bib0047","article-title":"Resistin as a risk factor for all-cause (and cardiovascular) death in the general population","volume":"12","author":"Del Cristo","year":"2022","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.ejim.2026.106893_bib0048","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.027621","article-title":"Human resistin induces cardiac dysfunction in pulmonary hypertension","volume":"12","author":"Lin","year":"2023","journal-title":"J Am Heart Assoc"},{"issue":"7","key":"10.1016\/j.ejim.2026.106893_bib0049","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1161\/ATVBAHA.109.186783","article-title":"Health ABC Study. Serum resistin concentrations and risk of new onset heart failure in older persons: the health, aging, and body composition (Health ABC) study","volume":"29","author":"Butler","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"10.1016\/j.ejim.2026.106893_bib0050","first-page":"267","article-title":"Is there a relationship between resistin levels and left ventricular end-diastolic pressure?","volume":"19","author":"Turgay Y\u0131ld\u0131r\u0131m","year":"2018","journal-title":"Anatol J Cardiol"},{"issue":"1","key":"10.1016\/j.ejim.2026.106893_bib0051","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.1016\/j.ijcard.2013.12.119","article-title":"High BNP levels in rheumatoid arthritis are related to inflammation but not to left ventricular abnormalities: a prospective case-control study","volume":"172","author":"George","year":"2014","journal-title":"Int J Cardiol"},{"issue":"2","key":"10.1016\/j.ejim.2026.106893_bib0052","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3899\/jrheum.130713","article-title":"Inflammation and disease activity are associated with high circulating cardiac markers in rheumatoid arthritis independently of traditional cardiovascular risk factors","volume":"41","author":"Avouac","year":"2014","journal-title":"J Rheumatol"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620526001986?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620526001986?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:07:05Z","timestamp":1788260825000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620526001986"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":52,"alternative-id":["S0953620526001986"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2026.106893","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fatty acid binding protein 4, resistin, diastolic dysfunction, and cardiovascular risk in patients with rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2026.106893","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Federation of Internal Medicine.","name":"copyright","label":"Copyright"}],"article-number":"106893"}}